NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company. Th ...

/NOT FOR DISSEMINATION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES/ VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aldebaran Resources Inc. (“Aldebaran” or the "Company") (TSX-V: ALDE, OTCQX: ADBRF) is pleased to announce the closing of its previously announced bought deal private placement offering (the “Offering”) of common shares of the Company (“Common Shares”). Pursuant to the Offering, the Compan ...

VivoPower to advise and support KWeather in procuring Ripple Lab shares, including some on its own balance sheet Balance of Ripple Lab shares held by VivoPower to be economically acquired by Lean Ventures VivoPower confirms it has not incurred any realized or unrealized losses on digital asset holdings VivoPower to receive $4.3million worth of KWeather shares representing 20% shareholding VivoPower to recycle profits and capital released to concentrate its focus and resources on its data center infrastructu ...

AS LHV Group invites investors and other interested parties to participate in a webinar introducing the Group’s new strategy, financial plan for 2026 and five-year financial forecast. The webinar will take place on 12 February at 13 p.m EET and will be held in English. The presentation will be hosted by: Mihkel Torim - Chief Executive Officer, LHV Group Meelis Paakspuu - Chief Financial Officer, LHV Group To participate in the webinar, please register in advance. During the webinar, participants will als ...

Core Viewpoint - NOVAGOLD Resources Inc. has successfully completed an upsized bought deal private placement, raising approximately US$310 million through the sale of 31,020,000 common shares at US$10.00 each, which will be utilized for Donlin Gold project activities, settling a promissory note with Barrick Mining Corporation, and general corporate purposes [1][2]. Group 1: Offering Details - The offering consisted of 31,020,000 common shares priced at US$10.00 each, resulting in gross proceeds of approximately US$310 million, including a partial exercise of the over-allotment option and participation from two cornerstone investors [1]. - Underwriters for the offering included BMO Capital Markets, RBC Capital Markets, and Scotiabank, who received a cash fee of 5% of the gross proceeds [2]. - The common shares were offered under various exemptions from prospectus requirements in Canada, the U.S., and other jurisdictions, with a minimum hold period of six months from the closing date [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to expenditures related to the Donlin Gold project, settling a prepayment option on a promissory note with Barrick, and for general corporate purposes [2][6]. Group 3: Company Overview - NOVAGOLD is focused on the development of the Donlin Gold project in Alaska, which is recognized as one of the safest mining jurisdictions globally, containing approximately 40 million ounces of gold in the Measured and Indicated Mineral Resource categories [5]. - The Donlin Gold project is expected to produce over one million ounces of gold annually over a 27-year mine life once in production, making it one of the largest and highest-grade open-pit gold deposits [5]. - As of November 30, 2025, the promissory note with Barrick, including accrued interest, amounted to approximately US$166.3 million, with an option to prepay US$100 million by December 3, 2026 [6].

Announces Oregon Mine Permitting DevelopmentsTORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Q-Gold Resources Ltd. (TSXV: QGR; OTCQB: QGLDF; Börse Frankfurt: QX9G) (“QGold” or the “Company”) is thrilled to announce the appointments of Catherine Callaghan as Director of Permitting and Community Affairs, and Wolfgang (Wolf) Schleiss as Director of Exploration – Quartz Mountain and Great Basin Region. These high-caliber additions bring unmatched expertise, project-specific knowledge, and deep local connections to p ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN; OTCQX: ERDCF) ("Erdene" or the "Company") is pleased to announce that further to its news release dated January 26, 2026, the Company has closed its bought deal private placement offering of 3,230,000 common shares of the Company (the “Common Shares”) at a price of $8.90 per Common Share for gross proc ...

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (ʺAltus Group” or “the Company”) (TSX: AIF) announced today it plans to release its financial results for the fourth quarter and fiscal year ended December 31, 2025 after market close on Thursday, February 19, 2026. Altus Group executives Mike Gordon, Chair and Chief Executive Officer (“CEO”), and Pawan Chhabra, Chief Financial Officer, will host a conference call at 5:00 p.m. (ET) the same day to discuss the results. Analysts who wish to ask qu ...

Core Insights - Longeveron Inc. supports the passing of the Mikaela Naylon Give Kids a Chance Act, which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program, incentivizing the development of treatments for rare pediatric diseases [2][3]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions [2][9]. - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy aimed at addressing unmet medical needs in various disease areas, including Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, and Pediatric Dilated Cardiomyopathy [9]. Legislative Impact - The Mikaela Naylon Give Kids a Chance Act allows companies to receive a priority review voucher upon FDA approval of a therapy for rare pediatric diseases, which can be used for expedited review of future therapies or sold [3][8]. - Since August 2024, these vouchers have been sold for $150-200 million each, with over 60 vouchers awarded for 40 pediatric diseases since the program's inception [3]. Clinical Development - Longeveron is currently conducting the ELPIS II Phase 2b clinical trial for laromestrocel in children with HLHS, enrolling 40 pediatric patients across twelve leading treatment institutions [5]. - Top-line results from the ELPIS II trial are expected in the third quarter of 2026, and if positive, the company plans to submit a Biological License Application (BLA) for full approval [5]. Unmet Medical Need - HLHS is a severe congenital heart defect with a high mortality rate, where only 50% of affected infants survive to adolescence despite current treatment options [4][6]. - There is a significant unmet medical need to improve right ventricular function in HLHS patients to enhance both short-term and long-term outcomes [6].

Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [3] - The lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity associated with current treatments [3] - Annamycin is in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3] Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for treating relapsed or refractory AML [4] - Following a successful Phase 1B/2 study (MB-106) and FDA input, the company believes it has de-risked the development pathway for Annamycin's potential approval [4] Additional Pipeline - Moleculin is also developing WP1066, an Immune/Transcription Modulator targeting brain tumors and pancreatic cancers by inhibiting oncogenic transcription factors [5] - The pipeline includes antimetabolites like WP1122, aimed at treating pathogenic viruses and certain cancer indications [5] Upcoming Events - The company will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026, with a presentation by Walter Klemp, the Founder, President, CEO, and Chairman [1]